82 related articles for article (PubMed ID: 29900832)
1. [Multi-omic approaches reveal new therapeutic targets for the treatment of pancreatic cancer].
Nicolle R; Blum Y; Marisa L; Dusetti N; Iovanna J
Med Sci (Paris); 2018 May; 34(5):379-382. PubMed ID: 29900832
[No Abstract] [Full Text] [Related]
2. The genomic profile of pancreatic adenocarcinoma and its relationship to metastatic disease.
Pierce KJ; de Abreu FB; Peterson JD; Suriawinata AA; Tsongalis GJ; Liu X
Exp Mol Pathol; 2016 Oct; 101(2):172-175. PubMed ID: 27498048
[No Abstract] [Full Text] [Related]
3. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia.
Hahn SA; Schmiegel WH
Digestion; 1998 Aug; 59(5):493-501. PubMed ID: 9705534
[TBL] [Abstract][Full Text] [Related]
4. Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics.
Yan Y; Gao R; Trinh TLP; Grant MB
Clin Cancer Res; 2017 Oct; 23(20):6363-6373. PubMed ID: 28684632
[No Abstract] [Full Text] [Related]
5. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies.
Le Large TYS; Bijlsma MF; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
Semin Cancer Biol; 2017 Jun; 44():153-169. PubMed ID: 28366542
[TBL] [Abstract][Full Text] [Related]
6. Familial aspects in carcinoma of the pancreas.
Ponz de Leon M
Recent Results Cancer Res; 1994; 136():265-74. PubMed ID: 7863099
[No Abstract] [Full Text] [Related]
7. Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas.
Lu L; Zeng J
PLoS One; 2017; 12(7):e0181532. PubMed ID: 28742845
[TBL] [Abstract][Full Text] [Related]
8. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
[TBL] [Abstract][Full Text] [Related]
9. Advances in the Genetics and Biology of Pancreatic Cancer.
Aguirre AJ; Collisson EA
Cancer J; 2017; 23(6):315-320. PubMed ID: 29189326
[TBL] [Abstract][Full Text] [Related]
10. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples.
Laurell H; Bouisson M; Berthelemy P; Rochaix P; Dejean S; Besse P; Susini C; Pradayrol L; Vaysse N; Buscail L
World J Gastroenterol; 2006 Jun; 12(21):3344-51. PubMed ID: 16733850
[TBL] [Abstract][Full Text] [Related]
11. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma.
Hua Z; Zhang YC; Hu XM; Jia ZG
World J Gastroenterol; 2003 Dec; 9(12):2764-7. PubMed ID: 14669329
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma.
Bittoni A; Piva F; Santoni M; Andrikou K; Conti A; Loretelli C; Mandolesi A; Lanese A; Pellei C; Scarpelli M; Principato G; Cascinu S
Future Oncol; 2015; 11(13):1905-17. PubMed ID: 26161927
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic basis of pancreatic adenocarcinoma.
Hilgers W; Kern SE
Genes Chromosomes Cancer; 1999 Sep; 26(1):1-12. PubMed ID: 10440999
[TBL] [Abstract][Full Text] [Related]
14. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of pancreatic cancer and potential targets of treatment.
Aho U; Zhao X; Löhr M; Andersson R
Scand J Gastroenterol; 2007 Mar; 42(3):279-96. PubMed ID: 17354106
[No Abstract] [Full Text] [Related]
16. A new platform for gene discovery in pancreatic cancer.
Callery MP
Gastroenterology; 2005 Aug; 129(2):763-4. PubMed ID: 16083736
[No Abstract] [Full Text] [Related]
17. Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer studies.
Nikolova O; Moser R; Kemp C; Gönen M; Margolin AA
Bioinformatics; 2017 May; 33(9):1362-1369. PubMed ID: 28082455
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.
Logsdon CD; Simeone DM; Binkley C; Arumugam T; Greenson JK; Giordano TJ; Misek DE; Kuick R; Hanash S
Cancer Res; 2003 May; 63(10):2649-57. PubMed ID: 12750293
[TBL] [Abstract][Full Text] [Related]
19. Correspondence re: Seki et al., Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin. Cancer Res., 7: 1976-1981, 2001.
Hindle KS; Kirkpatrick K; Mokbel K
Clin Cancer Res; 2002 Feb; 8(2):628-9. PubMed ID: 11839686
[No Abstract] [Full Text] [Related]
20. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
Argani P; Iacobuzio-Donahue C; Ryu B; Rosty C; Goggins M; Wilentz RE; Murugesan SR; Leach SD; Jaffee E; Yeo CJ; Cameron JL; Kern SE; Hruban RH
Clin Cancer Res; 2001 Dec; 7(12):3862-8. PubMed ID: 11751476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
